Immune-mediated hemolytic anemia (IMHA) in cats - part 1: a review
Immune-mediated hemolytic anemia (IMHA) in cats - part 1: a review
复制标题
DOI：
10.21825/vdt.87473
复制
发表时间：
2010-11-01
影响因子：
0.2
通讯作者：
Daminet, S.
中科院分区：
文献类型：
--
作者：
Paes, G.;Paepe, D.;Daminet, S.
与犬相反，免疫介导的溶血性贫血在猫中很少见到，并且最常继发于潜在的感染、肿瘤或炎症过程。临床症状通常是模糊的，并且是由严重贫血和缺氧对器官系统的影响引起的。患有IMHA的猫的实验室异常与犬中观察到的异常相当，除了球形红细胞，其在猫中很难鉴别。诊断是基于溶血性贫血结合阳性的“真”自身凝集和/或阳性的Coombs试验。应该始终进行潜在原因的研究，并且，因为嗜血支原体种类的感染是猫中IMHA的最重要的潜在原因，应进行聚合酶链反应试验以检测这些细菌。治疗包括免疫抑制药物、提供携氧溶液、治疗潜在病因和支持性护理。在猫中，IMHA的预后比狗好，尽管复发的频率相同
In contrast to dogs, immune-mediated hemolytic anemia is rarely seen in cats and occurs most often secondary to an underlying infectious, neoplastic or inflammatory process Clinical symptoms are often vague and are caused by severe anemia and the effect of hypoxia on organ systems Laboratory abnormalities in cats with IMHA are comparable to those seen in dogs, with the exception of spherocytes, which are difficult to identify in cats The diagnosis is based on hemolytic anemia in combination with a positive 'true' autoagglutination and/or a positive Coombs test A search for underlying causes should always be performed and, because infections with hemotrophic mycoplasma species are the most Important underlying cause for IMHA in cats, a polymerase chain reaction test to detect these bacteria should be carried out Treatment consists of immunosuppressive drugs, providing oxygen-carrying solutions, treating underlying causes and supportive care In cats, IMHA carries a better prognosis than in dogs, although relapses are seen in equal frequency